Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
05 oct. 2022 08h05 HE
|
Affimed N.V.
A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101) will be presentedIn a second poster presentation, initial phase 1 dose escalation...
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
04 sept. 2022 18h05 HE
|
Affimed N.V.
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable disease was observed in 10 of 27 evaluable...
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
11 août 2022 06h30 HE
|
Affimed N.V.
AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated...
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
04 août 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Establishes Scientific Advisory Board
30 juin 2022 16h00 HE
|
Affimed N.V.
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncologyScientific Advisory Board to provide guidance on...
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
10 juin 2022 10h31 HE
|
Affimed N.V.
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low levels of...
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
01 juin 2022 06h30 HE
|
Affimed N.V.
AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022AFM13 combination with NK...
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
26 mai 2022 17h05 HE
|
Affimed N.V.
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumorsDesign and rationale of the phase 1/2a study of...
Affimed to Present at the 2022 Jefferies Healthcare Conference
26 mai 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...